Drug Information

Drug General Information
Drug ID
D0T7US
Former ID
DAP000908
Drug Name
Eprosartan
Synonyms
SK&F 108566; SK-108566; SKF-108566; Teveten (TN); Eprosartan (USAN/INN); Eprosartan [USAN:BAN:INN]; SK&F-108566; (4-carboxybenzyl)imidazole-5-acrylic acid; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid
Drug Type
Small molecular drug
Indication Hypertension [ICD9: 401; ICD10:I10-I16] Approved [536361], [541182]
Therapeutic Class
Antihypertensive Agents
Company
Abbott Laboratories
Structure
Download
2D MOL

3D MOL
Formula
C23H24N2O4S
InChI
InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
InChIKey
OROAFUQRIXKEMV-LDADJPATSA-N
CAS Number
CAS 133040-01-4
PubChem Compound ID
5281037
PubChem Substance ID
9670, 7979177, 8616481, 14929623, 17398013, 26757976, 39289969, 46506765, 48415948, 49658621, 49830795, 50064350, 50303490, 81092802, 85209073, 91612944, 92308966, 93166188, 103213560, 103924435, 113854438, 117814116, 121277912, 126682167, 127329712, 127329713, 127329714, 127329715, 127329716, 127329717, 127329718, 127329719, 127329720, 127329721, 127329722, 127329723, 131835100, 134223577, 134338185, 135026481, 135650236, 136367951, 137002491, 142300349, 144115951, 162161427, 163389404, 164814942, 175266444, 176484078
ChEBI ID
ChEBI:4814
SuperDrug ATC ID
C09CA02
SuperDrug CAS ID
cas=133040014
Target and Pathway
Target(s) Type-1 angiotensin II receptor Target Info Antagonist [536887]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
Adrenergic signaling in cardiomyocytes
Vascular smooth muscle contraction
Renin-angiotensin system
Renin secretion
Pathways in cancer
NetPath Pathway TGF_beta_Receptor Signaling Pathway
PANTHER Pathway Angiotensin II-stimulated signaling through G proteins and beta-arrestin
Pathway Interaction Database Arf6 trafficking events
Arf6 signaling events
Angiopoietin receptor Tie2-mediated signaling
PathWhiz Pathway Angiotensin Metabolism
Muscle/Heart Contraction
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
WikiPathways ACE Inhibitor Pathway
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
Allograft Rejection
GPCR ligand binding
GPCR downstream signaling
References
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 541182(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 588).
Ref 536887Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.